🇺🇸 FDA
Pipeline program

PM359

Prime-0101

Phase 2 mab active

Quick answer

PM359 for Chronic Granulomatous Disease is a Phase 2 program (mab) at Prime Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Prime Medicine
Indication
Chronic Granulomatous Disease
Phase
Phase 2
Modality
mab
Status
active

Clinical trials